查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
結合疫苗全球市場規模調查和預測：按疾病適應症、病原體類型、最終用戶、地區2022-2029
市場調查報告書
商品編碼
1215431

結合疫苗全球市場規模調查和預測：按疾病適應症、病原體類型、最終用戶、地區2022-2029

Global Conjugate Vaccines Market Size study & Forecast, by Type by Disease Indication, by Pathogen Type, by End User and Regional Analysis, 2022-2029
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3個工作天內

價格

結合疫苗是一種亞單位疫苗，將強抗原作為載體與弱抗原結合，增強對弱抗原的免疫反應。

疫苗用於通過增強對抗原的免疫反應來抵禦 b 型流感嗜血桿菌 (Hib) 和肺炎鏈球菌等疾病。 政府的批准和肺炎球菌疾病全球流行率的上升是推動結合疫苗市場增長的主要因素。 因此，它可以在預測期內為市場產生有利可圖的需求。

結合疫苗廣泛用於預防肺炎球菌疾病。 因此，預計肺炎球菌疾病患病率的增加將在預測期內推動市場需求。 根據世界衛生組織的數據，2019 年肺炎導致 7,40,180 名五歲以下兒童死亡，佔該年齡組所有兒童死亡人數的 14%，但所有 1 至 5 歲兒童死亡人數佔所有兒科醫生死亡人數的 22%。 世界各地的兒童和家庭都受到肺炎的影響，但南亞和撒哈拉以南非洲的死亡率最高。 在市場參與者推出新產品的推動下，政府也越來越多地批准結合疫苗來控制各類疾病的傳播。 例如，2020 年 4 月，美國食品和藥物管理局 (FDA) 批准了 MenQuadfi 腦膜炎球菌結合疫苗的生物製品許可申請，□□用於治療 2 歲及以上人群的侵襲性腦膜炎球菌病。 此外，在預測期內，為開發有效疫苗而進行的持續研發活動將為市場創造有利可圖的機會。 然而，與結合疫苗相關的副作用增加將阻礙整個 2022-2029 年預測期內的市場增長。

全球結合疫苗市場研究考慮的主要區域包括亞太地區、北美、歐洲、拉丁美洲和世界其他地區。 由於該地區復雜醫療保健支出的增加和患者警惕性水平的提高，北美已成為世界市場份額的主導地區。 另一方面，由於主要市場參與者的存在以及政府對疫苗開發的支持增加等因素，預計亞太地區在預測期內將呈現高增長率。產生有利可圖的增長前景

這項研究的目的是定義近年來各個細分市場和國家的市場規模，並預測未來幾年的價值。 本報告旨在捕捉被調查國家行業的定性和定量方面的情況。

它還提供了關鍵方面的詳細信息，例如決定市場未來增長的驅動因素和挑戰。 此外，它還包含供利益相關者投資的微觀市場潛在機會，以及對主要參與者的競爭格局和產品供應的深入分析。

內容

第 1 章執行摘要

  • 市場概況
  • 2019-2029 年全球市場和細分的市場估計和預測
    • 結合疫苗市場：按地區劃分，2019-2029 年
    • 2019-2029 年按類型劃分的結合疫苗市場
    • 結合疫苗市場：按疾病適應症分類，2019-2029 年
    • 結合疫苗市場：按病原體類型，2019-2029 年
    • 結合疫苗市場：按最終用戶分類，2019-2029 年
  • 主要趨勢
  • 調查方法
  • 調查先決條件

第 2 章結合疫苗的全球市場定義和範圍

  • 調查的目的
  • 市場定義和範圍
    • 調查範圍
    • 工業發展
  • 調查年份
  • 貨幣兌換率

第3章結合疫苗全球市場動態

  • 結合疫苗市場影響分析 (2019-2029)
    • 市場驅動力
      • 政府對結合疫苗的批准增加
      • 肺炎球菌疾病的流行率上升
    • 市場挑戰
      • 與結合疫苗相關的副作用增加
    • 市場機會
      • 為有效開發疫苗而進行的持續研發活動

第四章全球疫苗市場行業分析

  • 波特 5 力模型
    • 供應商的議價能力
    • 買家的議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 競爭公司之間的敵對關係
  • 波特 5 力模型的未來方法 (2019-2029)
  • 害蟲分析
    • 政治
    • 經濟的
    • 社交
    • 技術
  • 投資招聘模式
  • 分析師的結論和建議
  • 頂級投資機會
  • 關鍵成功策略

第 5 章風險評估：COVID-19 的影響

  • 評估 COVID-19 對行業的總體影響
  • COVID-19 之前和 COVID-19 之後的市場情景

第 6 章全球結合疫苗市場，按類型

  • 市場概況
  • 結合疫苗的世界市場：按類型分類的性能 - 潛力分析
  • 2019-2029 年按類型分列的結合疫苗全球市場估計和預測
  • 全球結合疫苗市場細分分析
    • 單價結合疫苗
    • 多價結合疫苗

第 7 章：全球結合疫苗市場：按疾病和適應症分類

  • 市場概況
  • 結合疫苗的世界市場：按疾病、性能和潛力分析
  • 2019-2029 年世界結合疫苗市場、按疾病適應症估計和預測
  • 結合疫苗市場，細分分析
    • 肺炎球菌
    • 流感
    • 白喉破傷風百日咳 (DTP)
    • 腦膜炎球菌
    • 其他

第 8 章全球結合疫苗市場：按病原體類型分類

  • 市場概況
  • 結合疫苗的全球市場：按病原體類型、性能和潛力分析
  • 世界結合疫苗市場，按病原體類型估計和預測（2019-2029）
  • 結合疫苗市場，細分分析
    • 細菌結合疫苗
    • 病毒結合疫苗
    • 混合（病毒和細菌）結合疫苗

第 9 章結合疫苗的全球市場：按最終用戶分類

  • 市場概況
  • 結合疫苗的世界市場：最終用戶的性能潛力分析
  • 2019-2029 年全球結合疫苗市場、最終用戶估計和預測
  • 結合疫苗市場，細分分析
    • 兒科
    • 對於成年人

第 10 章全球結合疫苗市場：區域分析

  • 結合疫苗市場，按地區劃分的市場概況
  • 北美
    • 美國
      • 按類型估算和預測，2019-2029 年
      • 按疾病適應症估算和預測，2019-2029 年
      • 按病原體類型估算和預測，2019-2029 年
      • 2019-2029 年最終用戶的估計和預測
    • 加拿大
  • 歐洲結合疫苗市場概況
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 意大利
    • 其他歐洲地區
  • 亞太地區結合疫苗市場概況
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 韓國
    • 其他亞太地區
  • 拉丁美洲結合疫苗市場概況
    • 巴西
    • 墨西哥
  • 世界其他地區

第 11 章衝突信息

  • 頂級市場策略
  • 公司簡介
    • 諾華公司
      • 主要信息
      • 概覽
      • 財務信息（取決於數據可用性）
      • 產品概述
      • 近期趨勢
    • Neuron Biotech
    • Serum Institute of India
    • Pfizer, Inc.
    • Sanofi Pasteur
    • Bharat Biotech
    • Biological E Ltd.
    • GlaxoSmithKline, plc.
    • Merck and Company
    • CSL Limited

第 12 章研究過程

  • 研究過程
    • 數據挖掘
    • 分析
    • 市場評估
    • 驗證
    • 出版
  • 調查屬性
  • 調查先決條件

Global Conjugate Vaccines Market is valued approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. A conjugate vaccine is a kind of subunit vaccine that uses a strong antigen as a carrier to combine a weak antigen with, thus enhancing the immune system's response to the weak antigen. By enhancing an immune response to an antigen, vaccines are used to avoid diseases like Haemophilus influenzae B (Hib), pneumococcus and others. The key factor driving the market growth of conjugate vaccines is rising government approvals and prevalence of pneumococcal disease globally. Thus, create the lucrative demand for the market during forecast period.

The Conjugate Vaccines is widely used to avoid pneumococcus diseases. Thus, the increasing prevalence of pneumococcus diseases is anticipated to propelling demand for the market during forecast period. According to WHO, 7,40,180 children under the age of five died from pneumonia in 2019, accounting for 14% of all child deaths in that age group but 22% of all pediatric deaths in children from 1 to 5. Children and families worldwide are affected by pneumonia, but South Asia and sub-Saharan Africa have the highest death rates. Also, the rising government approval for Conjugate Vaccines to control the rising prevalence of various types of disease and encouraging market players for introducing a new product. For instance, in April 2020, U.S. Food and Drug Administration (FDA) approved the MenQuadfi Meningococcal Conjugate Vaccine's Biologics License Application for the treatment of invasive meningococcal disease in people two years of age and older. Also, the constant R&D activities for the development of effective vaccines would create the lucrative opportunity for the market during forecast period. However, the rising side effects associated with the conjugate vaccine stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Conjugate Vaccines Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the dominating region across the world in terms of market share, owing to the occurrence of the refined healthcare expenses and increasing the patient alertness level in the region. Whereas, Asia Pacific is also anticipated to exhibit highest growth rate over the forecast period, owing to factors such as presence of key market players and increasing support from the government for the vaccine development would create lucrative growth prospects for the Conjugate Vaccines market across Asia Pacific region.

Major market players included in this report are:

Novartis AG

Neuron Biotech

Serum Institute of India

Pfizer, Inc.

Sanofi Pasteur

Bharat Biotech

Biological E Ltd.

GlaxoSmithKline, plc.

Merck and Company

CSL Limited

Recent Developments in the Market:

  • In June 2021, Pfizer Inc. announced that the FDA has approved PREVNAR 20TM (Pneumococcal 20-valent Conjugate Vaccine) for use in people 18 years of age and older to prevent pneumonia and invasive disease brought on by the 20 pneumococcal serotypes contained in the vaccine.
  • In July 2021, Kenilworth, also known as MSD outside of the USA and Canada, announced that the U.S. Food and Drug Administration (FDA) had approved VAXNEUVANCETM (Pneumococcal 15-valent Conjugate Vaccine) (pronounced VAKS-noo-vans) for use in adults 18 years of age and older as an immunization for the prevention of invasive disease caused by streptococcus pneumoniae.

Global Conjugate Vaccines Market Report Scope:

Historical Data: 2019-2020-2021

Base Year for Estimation: 2021

Forecast period: 2022-2029

Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends

Segments Covered: Type, Disease Indication, Pathogen Type, End User, Region

Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World

Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:

Monovalent Conjugate Vaccines

Multivalent Conjugate Vaccines

By Disease Indication:

Pneumococcal

Influenza

Diphtheria Tetanus and Pertussis (DTP)

Meningococcal

Others

By Pathogen Type:

Bacterial Conjugate Vaccine

Viral Conjugate Vaccine

Combination (Viral and Bacterial) Conjugate Vaccine

By End User:

Pediatrics

Adults

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Conjugate Vaccines Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Conjugate Vaccines Market, by Type, 2019-2029 (USD Billion)
    • 1.2.3. Conjugate Vaccines Market, by Disease Indication, 2019-2029 (USD Billion)
    • 1.2.4. Conjugate Vaccines Market, by Pathogen Type, 2019-2029 (USD Billion)
    • 1.2.5. Conjugate Vaccines Market, by End User, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Conjugate Vaccines Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Conjugate Vaccines Market Dynamics

  • 3.1. Conjugate Vaccines Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Rising Government Approvals for Conjugate Vaccines
      • 3.1.1.2. Rising Prevalence of Pneumococcal Disease
    • 3.1.2. Market Challenges
      • 3.1.2.1. Rising side effects associated with the conjugate vaccine
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Constant R&D activities for the development of effective vaccines

Chapter 4. Global Conjugate Vaccines Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Investment Adoption Model
  • 4.5. Analyst Recommendation & Conclusion
  • 4.6. Top investment opportunity
  • 4.7. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Conjugate Vaccines Market, by Type

  • 6.1. Market Snapshot
  • 6.2. Global Conjugate Vaccines Market by Type, Performance - Potential Analysis
  • 6.3. Global Conjugate Vaccines Market Estimates & Forecasts by Type 2019-2029 (USD Billion)
  • 6.4. Conjugate Vaccines Market, Sub Segment Analysis
    • 6.4.1. Monovalent Conjugate Vaccines
    • 6.4.2. Multivalent Conjugate Vaccines

Chapter 7. Global Conjugate Vaccines Market, by Disease Indication

  • 7.1. Market Snapshot
  • 7.2. Global Conjugate Vaccines Market by Disease Indication, Performance - Potential Analysis
  • 7.3. Global Conjugate Vaccines Market Estimates & Forecasts by Disease Indication 2019-2029 (USD Billion)
  • 7.4. Conjugate Vaccines Market, Sub Segment Analysis
    • 7.4.1. Pneumococcal
    • 7.4.2. Influenza
    • 7.4.3. Diphtheria Tetanus and Pertussis (DTP)
    • 7.4.4. Meningococcal
    • 7.4.5. Others

Chapter 8. Global Conjugate Vaccines Market, by Pathogen Type

  • 8.1. Market Snapshot
  • 8.2. Global Conjugate Vaccines Market by Pathogen Type, Performance - Potential Analysis
  • 8.3. Global Conjugate Vaccines Market Estimates & Forecasts by Pathogen Type 2019-2029 (USD Billion)
  • 8.4. Conjugate Vaccines Market, Sub Segment Analysis
    • 8.4.1. Bacterial Conjugate Vaccine
    • 8.4.2. Viral Conjugate Vaccine
    • 8.4.3. Combination (Viral and Bacterial) Conjugate Vaccine

Chapter 9. Global Conjugate Vaccines Market, by End User

  • 9.1. Market Snapshot
  • 9.2. Global Conjugate Vaccines Market by End User, Performance - Potential Analysis
  • 9.3. Global Conjugate Vaccines Market Estimates & Forecasts by End User 2019-2029 (USD Billion)
  • 9.4. Conjugate Vaccines Market, Sub Segment Analysis
    • 9.4.1. Pediatrics
    • 9.4.2. Adults

Chapter 10. Global Conjugate Vaccines Market, Regional Analysis

  • 10.1. Conjugate Vaccines Market, Regional Market Snapshot
  • 10.2. North America Conjugate Vaccines Market
    • 10.2.1. U.S. Conjugate Vaccines Market
      • 10.2.1.1. Type breakdown estimates & forecasts, 2019-2029
      • 10.2.1.2. Disease Indication breakdown estimates & forecasts, 2019-2029
      • 10.2.1.3. Pathogen Type breakdown estimates & forecasts, 2019-2029
      • 10.2.1.4. End User breakdown estimates & forecasts, 2019-2029
    • 10.2.2. Canada Conjugate Vaccines Market
  • 10.3. Europe Conjugate Vaccines Market Snapshot
    • 10.3.1. U.K. Conjugate Vaccines Market
    • 10.3.2. Germany Conjugate Vaccines Market
    • 10.3.3. France Conjugate Vaccines Market
    • 10.3.4. Spain Conjugate Vaccines Market
    • 10.3.5. Italy Conjugate Vaccines Market
    • 10.3.6. Rest of Europe Conjugate Vaccines Market
  • 10.4. Asia-Pacific Conjugate Vaccines Market Snapshot
    • 10.4.1. China Conjugate Vaccines Market
    • 10.4.2. India Conjugate Vaccines Market
    • 10.4.3. Japan Conjugate Vaccines Market
    • 10.4.4. Australia Conjugate Vaccines Market
    • 10.4.5. South Korea Conjugate Vaccines Market
    • 10.4.6. Rest of Asia Pacific Conjugate Vaccines Market
  • 10.5. Latin America Conjugate Vaccines Market Snapshot
    • 10.5.1. Brazil Conjugate Vaccines Market
    • 10.5.2. Mexico Conjugate Vaccines Market
  • 10.6. Rest of The World Conjugate Vaccines Market

Chapter 11. Competitive Intelligence

  • 11.1. Top Market Strategies
  • 11.2. Company Profiles
    • 11.2.1. Novartis AG
      • 11.2.1.1. Key Information
      • 11.2.1.2. Overview
      • 11.2.1.3. Financial (Subject to Data Availability)
      • 11.2.1.4. Product Summary
      • 11.2.1.5. Recent Developments
    • 11.2.2. Neuron Biotech
    • 11.2.3. Serum Institute of India
    • 11.2.4. Pfizer, Inc.
    • 11.2.5. Sanofi Pasteur
    • 11.2.6. Bharat Biotech
    • 11.2.7. Biological E Ltd.
    • 11.2.8. GlaxoSmithKline, plc.
    • 11.2.9. Merck and Company
    • 11.2.10. CSL Limited

Chapter 12. Research Process

  • 12.1. Research Process
    • 12.1.1. Data Mining
    • 12.1.2. Analysis
    • 12.1.3. Market Estimation
    • 12.1.4. Validation
    • 12.1.5. Publishing
  • 12.2. Research Attributes
  • 12.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Conjugate Vaccines Market, report scope
  • TABLE 2. Global Conjugate Vaccines Market estimates & forecasts by Region 2019-2029 (USD Billion)
  • TABLE 3. Global Conjugate Vaccines Market estimates & forecasts by Type 2019-2029 (USD Billion)
  • TABLE 4. Global Conjugate Vaccines Market estimates & forecasts by Disease Indication 2019-2029 (USD Billion)
  • TABLE 5. Global Conjugate Vaccines Market estimates & forecasts by Pathogen Type 2019-2029 (USD Billion)
  • TABLE 6. Global Conjugate Vaccines Market estimates & forecasts by End User 2019-2029 (USD Billion)
  • TABLE 7. Global Conjugate Vaccines Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 8. Global Conjugate Vaccines Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 9. Global Conjugate Vaccines Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 10. Global Conjugate Vaccines Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 11. Global Conjugate Vaccines Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 12. Global Conjugate Vaccines Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 13. Global Conjugate Vaccines Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 14. Global Conjugate Vaccines Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 15. Global Conjugate Vaccines Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 16. Global Conjugate Vaccines Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 17. U.S. Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 18. U.S. Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 19. U.S. Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 20. Canada Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 21. Canada Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 22. Canada Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 23. UK Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 24. UK Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 25. UK Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 26. Germany Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 27. Germany Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 28. Germany Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 29. France Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 30. France Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 31. France Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 32. Italy Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 33. Italy Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 34. Italy Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 35. Spain Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 36. Spain Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 37. Spain Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 38. RoE Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 39. RoE Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 40. RoE Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 41. China Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 42. China Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 43. China Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 44. India Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 45. India Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 46. India Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 47. Japan Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 48. Japan Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 49. Japan Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 50. South Korea Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 51. South Korea Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 52. South Korea Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 53. Australia Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 54. Australia Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 55. Australia Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 56. RoAPAC Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 57. RoAPAC Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 58. RoAPAC Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 59. Brazil Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 60. Brazil Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 61. Brazil Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 62. Mexico Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 63. Mexico Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 64. Mexico Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 65. RoLA Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 66. RoLA Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 67. RoLA Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 68. Row Conjugate Vaccines Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 69. Row Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 70. Row Conjugate Vaccines Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 71. List of secondary sources, used in the study of global Conjugate Vaccines Market
  • TABLE 72. List of primary sources, used in the study of global Conjugate Vaccines Market
  • TABLE 73. Years considered for the study
  • TABLE 74. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Conjugate Vaccines Market, research methodology
  • FIG 2. Global Conjugate Vaccines Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Conjugate Vaccines Market, key trends 2021
  • FIG 5. Global Conjugate Vaccines Market, growth prospects 2022-2029
  • FIG 6. Global Conjugate Vaccines Market, porters 5 force model
  • FIG 7. Global Conjugate Vaccines Market, pest analysis
  • FIG 8. Global Conjugate Vaccines Market, value chain analysis
  • FIG 9. Global Conjugate Vaccines Market by segment, 2019 & 2029 (USD Billion)
  • FIG 10. Global Conjugate Vaccines Market by segment, 2019 & 2029 (USD Billion)
  • FIG 11. Global Conjugate Vaccines Market by segment, 2019 & 2029 (USD Billion)
  • FIG 12. Global Conjugate Vaccines Market by segment, 2019 & 2029 (USD Billion)
  • FIG 13. Global Conjugate Vaccines Market by segment, 2019 & 2029 (USD Billion)
  • FIG 14. Global Conjugate Vaccines Market, regional snapshot 2019 & 2029
  • FIG 15. North America Conjugate Vaccines Market 2019 & 2029 (USD Billion)
  • FIG 16. Europe Conjugate Vaccines Market 2019 & 2029 (USD Billion)
  • FIG 17. Asia pacific Conjugate Vaccines Market 2019 & 2029 (USD Billion)
  • FIG 18. Latin America Conjugate Vaccines Market 2019 & 2029 (USD Billion)
  • FIG 19. Global Conjugate Vaccines Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable